• Sisram Medical Ltd (Sisram Med, 01696) announced that its wholly-owned subsidiary, Sisram Medical HK, has signed a New Supply Framework Agreement with Fosun Wanbang (Jiangsu) Health Development, an indirect unit of controlling shareholder Shanghai Fosun Pharmaceutical (Fosun Pharma).

• Term & Product: The agreement runs from 10 Jun 2026 to 9 Jun 2029 and covers the supply of botulinum toxin type A for injection (DaxibotulinumtoxinA-lanm, branded DAXXIFY®/達希斐®) for mainland China.

• Financial caps: Aggregate transaction limits are set at: – US$6.20 million for 10 Jun–31 Dec 2026 – US$22.00 million for FY 2027 – US$44.00 million for FY 2028 – US$38.00 million for 1 Jan–9 Jun 2029 Total potential transaction value over the term: US$110.20 million.

• Pricing mechanism: Unit prices will be determined on a cost-plus basis, delivering a profit margin between 2.66% and 10.21%. Payments from Fosun Wanbang (Jiangsu) are due within 10 business days after it receives funds from downstream customers.

• Strategic rationale: Fosun Wanbang (Jiangsu) is one of the few PRC entities licensed to import and distribute toxic drugs and has nationwide coverage. The partnership supports Sisram Med’s accelerated commercial rollout of DAXXIFY® following its PRC quality clearance in early 2026.

• Governance & approvals: As Fosun Wanbang (Jiangsu) is a connected party, the arrangement constitutes a continuing connected transaction under HKEX rules. An extraordinary general meeting (EGM) will be held on 3 Aug 2026 to seek independent shareholders’ approval; Fosun-linked shareholder FPI (71.42% stake) will abstain from voting.

• Oversight: An Independent Board Committee and Rainbow Capital (Independent Financial Adviser) conclude the terms and caps are fair and reasonable, on normal commercial terms, and in the interests of independent shareholders. Internal controls include quarterly cap monitoring and annual reviews by independent directors and auditors.